Oxford Nanopore Technologies has announced the launch of a new Pharmacogenomics (PGx) Beta Program, combining Twist Bioscience's next-gen sequencing (NGS) technology with Oxford Nanopore's sequencing platform.
The newly launched solution is designed to deliver clear genetic results in a single process, reducing the need for supplementary tests. The pilot run has reportedly succeeded in fully resolving the complex CYP2D6 gene in a single attempt. The program is now available for research use.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.